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Abstract
Anhedonia is a core symptom of several psychiatric disorders but its biological underpinnings are poorly understood.
We performed a genome-wide association study of state anhedonia in 375,275 UK Biobank participants and assessed
for genetic correlation between anhedonia and neuropsychiatric conditions (major depressive disorder, schizophrenia,
bipolar disorder, obsessive compulsive disorder and Parkinson’s Disease). We then used a polygenic risk score approach
to test for association between genetic loading for anhedonia and both brain structure and brain function. This
included: magnetic resonance imaging (MRI) assessments of total grey matter volume, white matter volume,
cerebrospinal ﬂuid volume, and 15 cortical/subcortical regions of interest; diffusion tensor imaging (DTI) measures of
white matter tract integrity; and functional MRI activity during an emotion processing task. We identiﬁed 11 novel loci
associated at genome-wide signiﬁcance with anhedonia, with a SNP heritability estimate (h2SNP) of 5.6%. Strong
positive genetic correlations were found between anhedonia and major depressive disorder, schizophrenia and bipolar
disorder; but not with obsessive compulsive disorder or Parkinson’s Disease. Polygenic risk for anhedonia was associated
with poorer brain white matter integrity, smaller total grey matter volume, and smaller volumes of brain regions linked
to reward and pleasure processing, including orbito-frontal cortex. In summary, the identiﬁcation of novel anhedonia-
associated loci substantially expands our current understanding of the biological basis of state anhedonia and genetic
correlations with several psychiatric disorders conﬁrm the utility of this phenotype as a transdiagnostic marker of
vulnerability to mental illness. We also provide the ﬁrst evidence that genetic risk for state anhedonia inﬂuences brain
structure, including in regions associated with reward and pleasure processing.
Introduction
Anhedonia refers to reduced capacity to experience
pleasure in situations that individuals would normally
enjoy, and has been a focus of psychiatry research for
decades1,2. It constitutes a core symptom of several
neuropsychiatric disorders, including major depressive
disorder (MDD), schizophrenia, bipolar disorder and
obsessive compulsive disorder (OCD), as well as
Parkinson’s Disease (PD)3–6. Along with a direct nega-
tive association with quality of life and subjective
wellbeing, anhedonia is associated with multiple nega-
tive health-related behaviours, such as smoking, illicit
drug use, and low physical activity, even in the absence
of psychiatric disorder7,8. In line with a Research
Domain Criteria (RDoC) approach9, state anhedonia
can be measured and studied as a dimensional psy-
chopathological trait.
Anhedonia has been closely linked to the function and
structure of reward circuitry in the brain (primarily frontal,
striatal and limbic regions). These neurobiological associa-
tions are consistent with the view that anhedonia reﬂects
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dysfunction in reward processing10,11. Measures of anhe-
donia have been associated with altered functional activity
during reward-based tasks within frontal cortical regions
(medial frontal cortex) and subcortical striatal regions
(caudate and putamen)12, and with reduced volumes in a
similar set of frontal and striatal regions13,14. Anhedonia is
also associated with reduced white matter integrity15,16.
The genetic underpinnings of anhedonia are largely
unknown. Several GWAS of disorders where anhedonia is
a feature have been reported, such as MDD and schizo-
phrenia17,18. However, to date only small underpowered
GWAS studies of anhedonia have been published. A study
of 759 patients with MDD identiﬁed 18 SNPs associated
with an ‘interest-activity’ measure of anhedonia19. The
largest study to date is a mega-analysis of three studies of
young people from the UK and Sweden, with a total
sample size of 6579; a single locus was associated with
anhedonia in the discovery sample, but not in the repli-
cation sample20. A Finnish study examined genetic asso-
ciations with physical and social anhedonia, as assessed
with the Chapman scales21, in 3820 individuals but no
genome-wide signiﬁcant loci were identiﬁed22. Genetic
loci associated with anhedonia have therefore not yet been
reliably identiﬁed in large clinical or general population
samples23, and association tests of genetic risk for anhe-
donia with brain structure and function have not yet been
performed.
Here we report a large GWAS of state anhedonia within
the UK Biobank cohort. We also use a polygenic risk score
(PRS) approach to assess whether genetic loading for
anhedonia is associated with brain structure and brain
function.
Methods
UK Biobank sample
UK Biobank is a large cohort of over half a million UK
residents, aged between 39 and 73 years at baseline
assessment24. The cohort was designed to assess how
genetic, environmental and lifestyle factors inﬂuence a
range of morbidities in middle and older age. Baseline
assessments occurred over a 4-year recruitment period
(from 2006 to 2010) across 22 UK centres. These
assessments covered a wide range of social, cognitive,
lifestyle and physical health measures. Informed consent
was obtained from all participants, and this study was
conducted under generic approval from the NHS
National Research Ethics Service (approval letter dated
13 May 2016, Ref 16/NW/0274) and under UK Biobank
approvals for application #6553 ‘Genome-wide associa-
tion studies of mental health’ (PI Smith).
Genotyping, imputation and quality control
In March 2018 UK Biobank released genetic data for
487,409 individuals, genotyped using the Affymetrix UK
BiLEVE Axiom or the Affymetrix UK Biobank Axiom
arrays (Santa Clara, CA, USA), which have over 95% of
content in common22. Pre-imputation quality control,
imputation (both 1000Genomes and HRC Reference
Panels) and post-imputation cleaning were conducted
centrally by UK Biobank (described in the UK Biobank
release documentation, please see URLs in appendix for
details).
Phenotyping
As part of the comprehensive baseline assessment par-
ticipants were asked: “Over the past two weeks, how often
have you had little interest or pleasure in doing things?”
(Data ﬁeld 2060). Respondents could choose from the
following answers: “not at all”; “several days”; “more than
half the days”; and “nearly every day”. These responses
were coded as 0, 1, 2 and 3 respectively. This question on
anhedonia is derived from the Patient Health
Questionnaire-9 (PHQ-9), a well-validated screening
instrument for MDD25. To maximise numbers available
for downstream magnetic resonance imaging (MRI) ana-
lyses, we excluded from the primary GWAS those parti-
cipants with any available MRI data (n= 20,174).
Additional exclusion criteria for the GWAS included
individuals in whom: over 10% of genetic data were
missing; self-reported sex did not match genetic sex; sex
chromosome aneuploidy was reported; where hetero-
zygosity value was a clear outlier; and participants not of
European ancestry (n= 73,385).
Genetic association and heritability
Genetic association with the measure of anhedonia was
performed using BOLT-LMM26,27, which accounts for
population structure and sample relatedness by including
a genetic relatedness matrix within the models. Models
were further adjusted for age, sex, and genotyping array.
SNPs included in the analysis were ﬁltered by MAF > 0.01,
Hardy–Weinberg Equilibrium p > 1 × 10–6, and imputa-
tion score > 0.3. BOLT-LMM was also used to provide a
SNP-heritability estimate and an estimate of λGC.
Genetic correlations
Linkage Disequilibrium Score Regression (LDSR)28 was
carried out using LDSC on GWAS summary statistics from
several published studies, to obtain genetic correlations with
psychiatric disorders where anhedonia is known to be a
feature (MDD29, schizophrenia30, bipolar disorder30, and
OCD31), as well as Parkinson’s Disease32. We left the
intercept unconstrained to allow for sample overlap between
the sample used here and the outputs of the other GWAS.
Polygenic risk score generation
Polygenic risk scores (PRS) were created using
LDpred33. LDpred differs from the more common
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pruning and threshold (P&T) PRS because it generates a
single risk score for the trait of interest derived from as
many loci as possible. A training set was created to obtain
the LD structure by using 1000 unrelated Biobank parti-
cipants who had passed the same genetic QC as those
used in the GWAS (but who were excluded from the
GWAS because they did not respond to the anhedonia
question and had not provided brain imaging data). These
training data were then used for the construction of
anhedonia PRS in those participants for who brain ima-
ging data were available.
Brain imaging variables
A number of structural and functional brain MRI mea-
sures have been made available by UK Biobank as Imaging
Derived Phenotypes (IDPs)34. These measures are: total
volume (mm3) of brain grey matter, white matter and
cerebrospinal ﬂuid (CSF), each normalised for head size;
volumes (grey matter or total) of 15 cortical and sub-
cortical regions of interest (ROIs); diffusion tensor imaging
(DTI) measures of white matter integrity (fractional ani-
sotropy (FA) and mean diffusivity (MD)); and functional
MRI activity during an emotion processing task (the Hariri
face shape task)35 in an amygdala mask and group-deﬁned
mask consisting of occipito-temporal and amygdala
regions. For a more detailed description of these variables,
and for details of MRI acquisition and pre-processing and
IDP selection, please see supplementary methods.
Polygenic risk score and brain imaging analyses
MRI data were available for 20,174 UK Biobank parti-
cipants. PRS/MRI analyses were conducted in a subset of
17,120 participants who had available MRI data and who
were not included in the GWAS, after exclusion of par-
ticipants who did not meet genetic quality control criteria
(n= 2479) or who self-reported a developmental or
neurological disorder at either the baseline assessment or
the imaging visit (n= 575) (please see Table S1 for
exclusions). For each MRI outcome, data points with
values more than 3 standard deviations from the sample
mean were excluded.
Models were adjusted for age at MRI visit, (age at MRI)2,
sex, genotype array, the ﬁrst eight genetic principal com-
ponents, and lateral, transverse and longitudinal scanner
position covariates. Total tissue volume measures (total
grey matter, white matter and ventricular CSF volumes)
were normalised for head size prior to adjustment for the
above covariates. ROI analyses were additionally adjusted
for total brain volume (calculated by summing total grey
matter, white matter and ventricular cerebrospinal ﬂuid
(CSF) volume); and fMRI analyses were also adjusted for
head motion during the emotion processing task. False
Discovery Rate (FDR) correction was applied36,37.
Results
Demographics
The GWAS was performed on 375,724 UK Biobank
participants, of whom 203,322 (54.1%) were female. The
age of the sample ranged from 39 to 73 and the mean age
was 57 years (S.D.= 8.01). In response to the anhedonia
question, 299,232 (79.64%) answered “not at all”; 60,212
(16.0%) reported “several days”; 9405 (2.5%) reported
“more than half the days” and 6876 (1.8%) reported
“nearly every day”.
MRI analyses were conducted in 17,120 participants,
52.4% (8978) of whom were female. The mean age (at the
time of MRI) of these participants was 62.7 years (S.D.=
7.46; range= 45–80 years). Of the 16,783 participants
with available MRI data who answered the anhedonia
question, 13,810 (82.3%) responded “not at all”, 2469
(14.7%) reported feelings of anhedonia for “several days”,
297 (1.8%) for “more than half the days”, and 207 (1.2%)
“nearly every day”.
Genome-wide association study ﬁndings
GWAS results are presented as a Manhattan plot in Fig.
1, and details of genome-wide signiﬁcant loci are provided
in Table S2. In all, there were 1100 SNPs that were
genome-wide signiﬁcant (p < 5 × 10–8), and, of these,
represented 11 independent loci on 9 different chromo-
somes (Table S2; Figs. S1–S11). An independent signal
was deﬁned as the region of r2 > 0.1 within a 500MB
window from the most signiﬁcant SNP below genome-
wide signiﬁcance.
Some inﬂation of the GWAS results was observed
(λGC= 1.15), however considering the sample size this is
expected to have had a negligible impact on ﬁndings.
There was evidence for a polygenic component (LDSR
intercept= 1.03, S.E.= 0.005) and no evidence for undue
inﬂation of the test statistics due to unaccounted popu-
lation stratiﬁcation.
Genome-wide association study replication
To help validate the phenotype, we attempted a repli-
cation in the sample that was excluded from the GWAS.
Only one of the eleven loci identiﬁed achieved nominal
signiﬁcance (CHR6:27731402, β=−0.02, p= 0.015). This
would not survive correction for multiple testing. Of the
11 top hit SNPs, 8 of 11 coefﬁcients were in the same
direction as in the discovery set (Table S3).
Additionally, we determined if the PRS of anhedonia in
those excluded from the GWAS was associated with their
state anhedonia scores. The model was adjusted for the
ﬁrst 4 genetic principle components, genotyping chip, age,
sex and Townsend score. We detected a small but highly
signiﬁcant association between the anhedonia PRS and the
anhedonia phenotype scores (β= 0.0007, p= 1.17 × 10–14).
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Genetic correlations
Using LDSR we assessed whether genetic predisposition
to anhedonia overlapped with that for several psychiatric
disorders or traits. Anhedonia had signiﬁcant genetic
correlation with MDD (rg 0.77, q= 1.84 × 10
–139), schi-
zophrenia (rg 0.28, q= 5.28 × 10
–15) and bipolar disorder
(rg 0.12, q= 0.002) but not with OCD or Parkinson’s
disease (q= 0.6 and q= 0.97 respectively) (Table 1).
PRS and brain MRI structural and functional outcomes
Associations between PRS for anhedonia and total brain
tissue volumes are presented in Table S4. Greater poly-
genic risk for anhedonia was associated with lower total
grey matter volume, but not with total white matter
volume or with total ventricular CSF volume.
Associations were then assessed between PRS for
anhedonia and volumes of 15 cortical and subcortical
regions of interest (ROIs were derived a priori from meta-
analysis and literature review; please see Table S5 and
Supplementary Methods). Greater genetic risk score for
anhedonia was associated with smaller volumes for insular
cortex, orbitofrontal cortex, middle frontal gyrus and
anterior temporal fusiform cortex. Uncorrected associa-
tions were also observed with nucleus accumbens, medial
frontal cortex and caudate volumes, but these did not
survive FDR correction. The locations of the ROIs
showing signiﬁcant association with the PRS are displayed
in Supplementary Fig. S12, and a point-range plot show-
ing the association evidence for ROI volumes is displayed
in Fig. 2a.
In subsequent analyses of association with white matter
integrity, greater PRS for anhedonia was not associated
with general factors of either higher mean diffusivity
(MD) or fractional anisotropy (FA) (Table S6). PRS
associations were assessed with 15 individual white matter
tracts (bilateral tracts were combined in the same models
and models were adjusted for hemisphere; see Supple-
mentary Methods, Supplementary Tables S7 and S8 for
tract-speciﬁc FA and MD results, respectively). Higher
PRS for anhedonia was associated with lower FA in four of
the ﬁfteen tracts (anterior thalamic radiation, forceps
minor, medial lemniscus, posterior thalamic radiation)
(Fig. 2b). Higher PRS for anhedonia was also associated
with higher MD in 9 of the 15 tracts (all apart from
acoustic radiation, corticospinal tract, forceps major,
inferior longitudinal fasciculus, medial lemniscus and
parahippocampal part of cingulum) (Fig. 2c). There was
no association between PRS for anhedonia and functional
MRI activity during the emotion-processing task (median
Blood Oxygen Level Dependent signal for the face vs.
shape contrast) (Table S9).
Discussion
These analyses represent the largest genetic association
study of state anhedonia performed to date. We identiﬁed
eleven genetic loci associated with anhedonia in the UK
Fig. 1 Anhedonia GWAS results. Results are presented as a Manhattan Plot and as a QQ plot (inset). Association analysis p-values for each SNP are
plotted (as –log10(p)) vs. chromosomal position. The red and blue lines indicate the genome-wide signiﬁcant and suggestive p-value thresholds,
respectively. The QQ plot shows observed vs expected p-values for every SNP.
Table 1 Genetic correlations of anhedonia with
psychiatric phenotypes.
Trait rg S.E. Z p q
MDD 0.771 0.0306 25.2033 3.68E-140 1.84E-139
Schizophrenia 0.28 0.0353 7.9345 2.11E-15 5.28E-15
Bipolar 0.122 0.038 3.2187 0.00129 0.002
Parkinson’s Disease 0.0584 0.0837 0.6978 0.4853 0.60
OCD −0.0023 0.0618 −0.0372 0.9704 0.97
rg genetic correlation with mood instability, S.E. standard error of the genetic
correlation, Z the test statistic, p the p value, q the False discovery rate corrected
p value. MDDmajor depressive disorder, PTSD post-traumatic stress disorder.
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general population. Within each associated region there
were a number of genes that could have a functional
impact on anhedonia and the pleasure cycle (considered
in detail below). Consistent with an RDoC approach
focusing on transdiagnostic symptoms and traits, we
found strong genetic correlations between anhedonia and
MDD, schizophrenia and bipolar disorder, but not
between anhedonia and OCD or Parkinson’s Disease.
Despite the lack of correlation with Parkinson’s Disease,
several of the loci identiﬁed in our GWAS include genes
with known association with Parkinson’s Disease (see
below). We also report the ﬁrst investigation of associa-
tions between genetic loading for anhedonia and both
brain structure and brain function.
Genes within anhedonia-associated loci
There are multiple genes in each QTL identiﬁed in the
GWAS. Here we discuss potentially relevant genes based
on their known function in the scientiﬁc literature.
Within the chromosome 1 locus there are multiple RGS
genes, most notably RGS1 and RGS2, encoding regulators
of G-protein signalling that show prominent expression in
the brain38. RGS2 has previously been identiﬁed as a
modulator of LRRK239 expression, a gene known to be a
genetic cause of Parkinson’s Disease. RGS2 has also been
associated with symptom severity in schizophrenia40 and
lower expression of RGS2 may be related to depression-
like behaviours in animal models41.
EPHB1 on chromosome 3 encodes an ephrin receptor
tyrosine kinase identiﬁed in a GWAS of antidepressant
response42, and is associated with symptoms of schizo-
phrenia in Chinese Han populations43, and with sus-
ceptibility to Parkinson’s Disease44.
At the more centromeric locus on chromosome 11,
GRM5 encodes a metabotropic glutamate receptor that
has been extensively studied in relation to MDD45,46 and
schizophrenia47,48. Assessments in mice have also found
that agonists of GRM5 attenuate Parkinsonian motor
deﬁcits via striatal dopamine depletion49. The Genotype
Tissue Expression (GTEx) database38 shows prominent
expression of GRM5 in the brain, especially within the
nucleus accumbens, a region with a major role in the
prediction of reward50,51.
Another likely candidate gene at this chromosome 11
locus is DISC1FP1. DISC1 (Disrupted in Schizophrenia 1),
a gene located on chromosome 1, is part of a chromosome
1:11 translocation that increases risk of schizophrenia,
schizoaffective disorder and bipolar disorder52. DISC1FP1
is disrupted by this translocation, impacting on both
intracellular NADH oxidoreductase activities and protein
translation53.
At the more telomeric locus on chromosome 11, NCAM1
(neural cell adhesion molecule 1) has been implicated as a
potential link between depressive symptoms and brain
structure54, speciﬁcally decreased FA. NCAM1 has been
reported to be present at increased levels in the amygdala38,
another brain region associated with the pleasure cycle, in
depressed subjects55. However, we did not ﬁnd any asso-
ciation between PRS for anhedonia and either amygdala
volume or functional activity in the amygdala during an
emotion processing task. It is possible that NCAM1 may
exert its effects via expression in other brain regions.
Another gene of interest at this second chromosome 11
locus is DRD2, encoding the dopamine D2 receptor. There
is an extensive literature on the importance of DRD2 for the
psychopharmacology of both schizophrenia and MDD56,57.
The chromosome 12 locus contains only LOC and LINC
genes. These encode different classes of functional RNA
but little is known about their function beyond possible
post-transcriptional regulation of other gene products.
The more centromeric locus on chromosome 14 con-
tains PRKD1, which encodes a serine/threonine-protein
Fig. 2 Plots of associations (regression coefﬁcients and 95% conﬁdence intervals (CI)) between polygenic risk for anhedonia and a regional volumes
of cortical/subcortical ROIs; b tract-speciﬁc fractional anisotropy; and c tract-speciﬁc mean diffusivity.
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kinase identiﬁed in a GWAS of schizophrenia18. The more
telomeric locus on chromosome 14 contains the gene
SLC8A3, a gene involved in maintaining Ca2+ homo-
eostasis within a variety of tissues, including neurons.
SLC8A3 may also play a role in Parkinson’s Disease58.
ISLR2 on chromosome 15 is involved in neurodeve-
lopment59 but its role in psychiatric and neurological
traits is not well characterised. Another candidate gene
within this locus, NRG4, encodes a neuregulin protein
that activates type-1 growth factor receptors. Recent work
has shown that NRG4 acts a regulator of the growth and
elaboration of pyramidal neuron dendrites in the devel-
oping neocortex60. Pyramidal neurons have been directly
implicated in the pathophysiology of schizophrenia61.
Finally, on chromosome 18, DCC (the most signiﬁcant
hit) encodes a netrin 1 receptor with a role in axon gui-
dance, and has been previously reported to be associated
with anhedonic phenotypes in mice and humans62 and
potentially with schizophrenia pathogenesis63. We have
previously identiﬁed DCC in GWAS of mood instability64,
suicidality65 and multisite chronic pain66.
Brain structure and function
Our ﬁndings on the relationship between genetic loading
for anhedonia and brain structure and function are of
considerable interest. Greater levels of anhedonia, in healthy
and clinical populations, have been linked to altered func-
tional activity (and less consistently to reduced volume) in
frontal/striatal regions involved in reward or pleasure pro-
cessing12–14,67–71. The regions most consistently implicated
include nucleus accumbens, caudate, putamen, medial
frontal cortex and orbitofrontal cortex.
We found that increased genetic risk for anhedonia was
associated with smaller volumes of the orbitofrontal cor-
tex the (Fig. 2a; Supplementary Fig. 1) a region involved in
representation of reward value and social reward depen-
dence70,72. We also noted uncorrected associations of PRS
for anhedonia and smaller volumes of nucleus accumbens
(involved in reward value and pleasure processing69,73)
and medial frontal cortex (linked to pleasure proces-
sing69), but these associations did not survive correction
for multiple comparisons. These cortical/subcortical
volume ﬁndings are therefore consistent with an asso-
ciation between genetic risk for anhedonia and reward/
pleasure processing73.
Increased genetic risk for anhedonia was also associated
with smaller volumes of insular cortex (associated with
emotion processing74) and fusiform cortex. Most ROIs in
our analysis were selected on the basis that they were
associated with smaller volumes in MDD vs. healthy con-
trols in the most recent MDD brain structure meta-
analysis75. Our ﬁndings are consistent with two scenarios:
either, genes for anhedonia partly mediate the association
between the ROI volumes and MDD, or these genes exhibit
horizontal pleiotropy and affect both phenotypes via sepa-
rate mechanisms. Consistent with our ﬁnding of widespread
associations of genetic risk for anhedonia with cortical/
subcortical volumes, we also found an association with
reduced total grey matter volume, adjusted for head size.
Evidence of reduced white matter integrity (FA) in
several tracts in individuals scoring higher on measures of
anhedonia has been reported16,76. We found that higher
values for the anhedonia PRS were associated with higher
MD (reﬂecting poorer white matter integrity), in most
individual tracts, but not in a general factor of MD. Sev-
eral tracts also showed reduced FA.
We did not, however, ﬁnd any association between PRS
for state anhedonia and functional brain activity. UK
Biobank ROIs were selected based on average responses
during an emotion processing task; it is therefore plau-
sible that effects would emerge with the use of a reward
processing task, or by applying whole-brain voxel-wise
analyses, to include further reward/pleasure processing
regions.
Strengths and limitations
This study is the largest GWAS of state anhedonia to
date, and substantially contributes new knowledge on the
biology of this important transdiagnostic symptom. We
conducted analyses within a large population-based
cohort. Our primary analysis included individuals with
mental health histories, but these represent only a small
proportion of the total sample, which is an order of
magnitude larger than any previous study of this kind.
Subclinical anhedonia is common, and associated with
increased risk of later mental illness77. This idea is rein-
forced by the signiﬁcant genetic correlations with other
psychiatric disorders. Additionally, we used an ordered
ordinal phenotype, resulting in more power to detect
associations than with the more common dichotomised
(‘non-anhedonic’ vs. ‘anhedonic’) analyses78. Identiﬁcation
of loci associated with population-level anhedonia may be
important from a personalised medicine perspective, for
example, in terms of developing stratiﬁed medicine
approaches to identify individuals at high-risk of devel-
oping psychiatric disorders.
Notably, however, the UK Biobank cohort has a degree of
selection bias. In general, volunteers are typically healthier
and of higher socioeconomic status and higher education
level than the general population79, so reported levels of
anhedonia in this sample may be lower than the population
rate. Therefore, it is plausible that the strength of associa-
tions we identiﬁed may be an underestimate of the true
population value; there may also be an inﬂated type 2
error rate.
The measure of anhedonia employed here was a single
question from a depression screening instrument, the
PHQ-9, assessing frequency of symptoms anhedonia
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within the preceding two weeks. This item therefore
measures state anhedonia at a single time point, and
clearly could be inﬂuenced by environmental factors, such
as season or current health status80,81. However, we have
assumed here that despite transient environmental and
physical factors, individuals who are prone to trait anhe-
donia will be more likely to report higher frequency of
anhedonia at any given time point, and it seems likely that
a recent anhedonia phenotype will be enriched for indi-
viduals with stronger genetic predisposition towards
anhedonia. In line with this assumption, the anhedonia
item of the PHQ-9 at a single time point has demon-
strated utility in predicting longitudinal brain structural
change82.
Additionally, our attempts at replication of the GWAS
results met with limited success, with no real replication
of the top hits. However, the PRS analysis was able to
detect a signiﬁcant correlation with state anhedonia in the
replication sample. We attribute the lack of replication
success in the GWAS to lack of power (small replication
sample size) and small effect sizes for individual SNPs.
The GWAS treated the ordered ordinal responses to the
frequency of anhedonia question as linear. This approach is
likely to have had a minimal impact on the BOLT-LMM
GWAS results. Although the distance between points on the
anhedonia scale is not evenly spaced, each point can rea-
sonably be considered to be at least several days of anhe-
donia in the preceding two weeks than the point before it.
The anhedonia measure did not enable determination of
speciﬁc anhedonia subtypes. Existing validated instru-
ments typically divide anhedonia into physical and social
subscales21, or into anticipatory vs. consummatory com-
ponents of pleasure83. Future studies using more detailed
anhedonia scales may be of use in examining the extent of
genetic overlap between anhedonia subtypes.
Conclusion
We report the largest GWAS to date of state anhedonia, a
common symptom associated with several psychiatric dis-
orders. We identiﬁed 11 novel genetic loci and our ﬁndings
indicate substantial genetic overlap between anhedonia and
several psychiatric disorders including MDD, schizophrenia
and bipolar disorder. PRS analyses revealed association
between genetic loading for anhedonia and smaller volumes
of several brain regions, and poorer white matter integrity.
Taken together, these ﬁndings provide important insights
into the neurobiology of an important but under-studied
psychiatric symptom and strongly support the proposition
that genetic predisposition to anhedonia inﬂuences brain
structure and function.
URLs
UK Biobank genetic data release information - https://
data.bris.ac.uk/datasets/3074krb6t2frj29yh2b03x3wxj/UK
%20Biobank%20Genetic%20Data_MRC%20IEU%20
Quality%20Control%20version%201.pdf. Genotyping and
quality control information – http://www.ukbiobank.ac.uk/
wp-content/uploads/2014/04/UKBiobank_genotyping_
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